Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, Connecticut, USA.
Psychother Psychosom. 2024;93(1):8-23. doi: 10.1159/000535665. Epub 2024 Jan 25.
Cognitive dysfunction or deficits are common in patients with major depressive disorder (MDD). The current study systematically reviews and meta-analyzes multiple domains of cognitive impairment in patients with MDD.
PubMed/MEDLINE, PsycINFO, Cochrane Library, Embase, Web of Science, and Google Scholar were searched from inception through May 17, 2023, with no language limits. Studies with the following inclusion criteria were included: (1) patients with a diagnosis of MDD using standardized diagnostic criteria; (2) healthy controls (i.e., those without MDD); (3) neuropsychological assessments of cognitive impairment using Cambridge Neuropsychological Test Automated Battery (CANTAB); and (4) reports of sufficient data to quantify standardized effect sizes. Hedges' g standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) were used to quantify effect sizes of cognitive impairments in MDD. SMDs were estimated using a fixed- or random-effects models.
Overall, 33 studies consisting of 2,596 subjects (n = 1,337 for patients with MDD and n = 1,259 for healthy controls) were included. Patients with MDD, when compared to healthy controls, had moderate cognitive deficits (SMD, -0.39 [95% CI, -0.47 to -0.31]). In our subgroup analyses, patients with treatment-resistant depression (SMD, -0.56 [95% CI, -0.78 to -0.34]) and older adults with MDD (SMD, -0.51 [95% CI, -0.66 to -0.36]) had greater cognitive deficits than healthy controls. The effect size was small among unmedicated patients with MDD (SMD, -0.19 [95% CI, -0.37 to -0.00]), and we did not find any statistical difference among children. Cognitive deficits were consistently found in all domains, except the reaction time. No publication bias was reported.
Because cognitive impairment in MDD can persist in remission or increase the risk of major neurodegenerative disorders, remediation of cognitive impairment in addition to alleviation of depressive symptoms should be an important goal when treating patients with MDD.
认知功能障碍或缺陷在患有重度抑郁症(MDD)的患者中很常见。本研究系统地综述和荟萃分析了 MDD 患者多个认知领域的损伤。
从建库至 2023 年 5 月 17 日,通过 PubMed/MEDLINE、PsycINFO、Cochrane 图书馆、Embase、Web of Science 和 Google Scholar 进行了检索,不设语言限制。纳入符合以下标准的研究:(1)使用标准化诊断标准诊断为 MDD 的患者;(2)健康对照组(即无 MDD 的患者);(3)使用剑桥神经心理学测试自动化电池(CANTAB)进行认知障碍的神经心理学评估;以及(4)报告了足够的数据以量化标准化效应量。使用 Hedges'g 标准化均数差(SMD)及其相应的 95%置信区间(CI)来量化 MDD 患者的认知损伤的效应量。使用固定或随机效应模型估计 SMD。
共有 33 项研究,包括 2596 名受试者(n = 1337 名 MDD 患者,n = 1259 名健康对照组)被纳入。与健康对照组相比,MDD 患者存在中度认知缺陷(SMD,-0.39 [95%CI,-0.47 至 -0.31])。在我们的亚组分析中,治疗抵抗性抑郁症患者(SMD,-0.56 [95%CI,-0.78 至 -0.34])和老年 MDD 患者(SMD,-0.51 [95%CI,-0.66 至 -0.36])的认知缺陷大于健康对照组。未用药的 MDD 患者的效应量较小(SMD,-0.19 [95%CI,-0.37 至 -0.00]),且在儿童中未发现任何统计学差异。在所有领域都发现了认知缺陷,除了反应时间。未报告发表偏倚。
由于 MDD 中的认知障碍可以在缓解期持续存在或增加主要神经退行性疾病的风险,因此在治疗 MDD 患者时,除缓解抑郁症状外,矫正认知障碍应成为一个重要目标。